The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60. Health ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

Fact checked by Jennifer Klump A group of advisors to the Centers for Disease Control and Prevention (CDC) voted 5-2 to ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new preventive shot against ...